Skip to main content
Erschienen in: European Journal of Nutrition 4/2016

10.07.2015 | Original Contribution

Pomegranate inhibits neuroinflammation and amyloidogenesis in IL-1β-stimulated SK-N-SH cells

verfasst von: Ravikanth Velagapudi, Gina Baco, Sunjeet Khela, Uchechukwu Okorji, Olumayokun Olajide

Erschienen in: European Journal of Nutrition | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Pomegranate fruit, Punica granatum L. (Punicaceae), and its constituents have been shown to inhibit inflammation. In this study, we aimed to assess the effects of freeze-dried pomegranate (PWE) on PGE2 production in IL-1β-stimulated SK-N-SH cells.

Methods

An enzyme immunoassay (EIA) was used to measure prostaglandin E2 (PGE2) production from supernatants of IL-1β-stimulated SK-N-SH cells. Expression of COX-2, phospho-IκB, and phospho-IKK proteins was evaluated, while NF-κB reporter gene assay was carried out in TNFα-stimulated HEK293 cells to determine the effect of PWE on NF-κB transactivation. Levels of BACE-1 and Aβ in SK-N-SH cells stimulated with IL-1β were measured with an in cell ELISA.

Results

PWE (25–200 μg/ml) dose dependently reduced COX-2-dependent PGE2 production in SK-N-SH cells stimulated with IL-1β. Phosphorylation of IκB and IKK was significantly (p < 0.001) inhibited by PWE (50–200 μg/ml). Our studies also show that PWE (50–200 μg/ml) significantly (p < 0.01) inhibited NF-κB transactivation in TNFα-stimulated HEK293 cells. Furthermore, PWE inhibited BACE-1 and Aβ expression in SK-N-SH cells treated with IL-1β.

Conclusions

Taken together, our study demonstrates that pomegranate inhibits inflammation, as well as amyloidogenesis in IL-1β-stimulated SK-N-SH cells. We propose that pomegranate is a potential nutritional strategy in slowing the progression of neurodegenerative disorders such as Alzheimer’s disease.
Literatur
1.
Zurück zum Zitat Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer’s disease. Lancet 368:387–403CrossRef Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer’s disease. Lancet 368:387–403CrossRef
2.
Zurück zum Zitat Castellani RK, Rolston RK, Smith MA (2010) Alzheimer disease. Dis Mon 56:484–546CrossRef Castellani RK, Rolston RK, Smith MA (2010) Alzheimer disease. Dis Mon 56:484–546CrossRef
3.
Zurück zum Zitat Selkoe DJ (2001) Alzheimer’s disease. Genes, proteins, and therapy. Physiol Rev 81:741–766 Selkoe DJ (2001) Alzheimer’s disease. Genes, proteins, and therapy. Physiol Rev 81:741–766
4.
Zurück zum Zitat Messmer K, Reynolds GP (2005) An in vitro model of inflammatory neurodegeneration and its neuroprotection. Neurosci Lett 388:39–44CrossRef Messmer K, Reynolds GP (2005) An in vitro model of inflammatory neurodegeneration and its neuroprotection. Neurosci Lett 388:39–44CrossRef
5.
Zurück zum Zitat Chen CH, Zhou W, Liu S, Deng Y, Cai F, Tone M, Tone Y, Tong Y, Song W (2012) Increased NF-κB signalling up-regulates BACE1 expression and its therapeutic potential in Alzheimer’s disease. Int J Neuropsychopharmacol 15:77–90CrossRef Chen CH, Zhou W, Liu S, Deng Y, Cai F, Tone M, Tone Y, Tong Y, Song W (2012) Increased NF-κB signalling up-regulates BACE1 expression and its therapeutic potential in Alzheimer’s disease. Int J Neuropsychopharmacol 15:77–90CrossRef
6.
Zurück zum Zitat HoshinoT NT, Homan T, Tanaka K, Sugimoto Y, Araki W, Narita M, Narumiya S, Suzuki T, Mizushima T (2007) Involvement of prostaglandin E2 in production of amyloid-peptides both in vitro and in vivo. J Biol Chem 282:32676–32688CrossRef HoshinoT NT, Homan T, Tanaka K, Sugimoto Y, Araki W, Narita M, Narumiya S, Suzuki T, Mizushima T (2007) Involvement of prostaglandin E2 in production of amyloid-peptides both in vitro and in vivo. J Biol Chem 282:32676–32688CrossRef
7.
Zurück zum Zitat Yasojima K, Schwab C, McGeer EG, McGeer PL (1999) Distribution of cyclooxygenase-1 and cyclooxygenase-2 mRNAs and proteins in human brain and peripheral organs. Brain Res 830:226–236CrossRef Yasojima K, Schwab C, McGeer EG, McGeer PL (1999) Distribution of cyclooxygenase-1 and cyclooxygenase-2 mRNAs and proteins in human brain and peripheral organs. Brain Res 830:226–236CrossRef
8.
Zurück zum Zitat Montine TJ, Sidell KR, Crews BC, Markesbery WR, Marnett LJ, Roberts LJ 2nd, Morrow JD (1999) Elevated CSF prostaglandin E2 levels in patients with probable AD. Neurology 53:1495–1498CrossRef Montine TJ, Sidell KR, Crews BC, Markesbery WR, Marnett LJ, Roberts LJ 2nd, Morrow JD (1999) Elevated CSF prostaglandin E2 levels in patients with probable AD. Neurology 53:1495–1498CrossRef
9.
Zurück zum Zitat Paris D, Patel N, Quadros A, Linan M, Bakshi P, Ait-Ghezala G, Mullan M (2007) Inhibition of Abeta production by NF-kappaB inhibitors. Neurosci Lett 415:11–16CrossRef Paris D, Patel N, Quadros A, Linan M, Bakshi P, Ait-Ghezala G, Mullan M (2007) Inhibition of Abeta production by NF-kappaB inhibitors. Neurosci Lett 415:11–16CrossRef
10.
Zurück zum Zitat Bales KR, Du Y, Dodel RC, Yan GM, Hamilton-Byrd E, Paul SM (1998) The NF–kappaB/Rel family of proteins mediates Abeta-induced neurotoxicity and glial activation. Brain Res Mol Brain Res 57:63–72CrossRef Bales KR, Du Y, Dodel RC, Yan GM, Hamilton-Byrd E, Paul SM (1998) The NF–kappaB/Rel family of proteins mediates Abeta-induced neurotoxicity and glial activation. Brain Res Mol Brain Res 57:63–72CrossRef
11.
Zurück zum Zitat Marwarha G, Raza S, Meiers C, Ghribi O (2014) Leptin attenuates BACE1 expression and amyloid-β genesis via the activation of SIRT1 signaling pathway. Biochim Biophys Acta 1842:1587–1595CrossRef Marwarha G, Raza S, Meiers C, Ghribi O (2014) Leptin attenuates BACE1 expression and amyloid-β genesis via the activation of SIRT1 signaling pathway. Biochim Biophys Acta 1842:1587–1595CrossRef
12.
Zurück zum Zitat Bourne KZ, Ferrari DC, Lange-Dohna C, Rossner S, Wood TG, Perez-Polo JR (2007) Differential regulation of BACE1 promoter activity by NFB in neurons and glia upon exposure to Ab peptides. J Neurosci Res 85:1194–1204CrossRef Bourne KZ, Ferrari DC, Lange-Dohna C, Rossner S, Wood TG, Perez-Polo JR (2007) Differential regulation of BACE1 promoter activity by NFB in neurons and glia upon exposure to Ab peptides. J Neurosci Res 85:1194–1204CrossRef
13.
Zurück zum Zitat Buggia-Prevot V, Sevalle J, Rossner S, Checler F (2008) NFkappaB-dependent control of BACE1 promoter transactivation by Abeta42. J Biol Chem 283:10037–10047CrossRef Buggia-Prevot V, Sevalle J, Rossner S, Checler F (2008) NFkappaB-dependent control of BACE1 promoter transactivation by Abeta42. J Biol Chem 283:10037–10047CrossRef
14.
Zurück zum Zitat Guglielmotto M, Aragno M, Tamagno E, Vercellinatto I, Visentin S, Medana C, Catalano MG, Smith MA, Perry G, Danni O, Boccuzzi G, Tabaton M (2012) AGEs/RAGE complex upregulates BACE1 via NF-κB pathway activation. Neurobiol Aging 33:196-e13–196-e27CrossRef Guglielmotto M, Aragno M, Tamagno E, Vercellinatto I, Visentin S, Medana C, Catalano MG, Smith MA, Perry G, Danni O, Boccuzzi G, Tabaton M (2012) AGEs/RAGE complex upregulates BACE1 via NF-κB pathway activation. Neurobiol Aging 33:196-e13–196-e27CrossRef
15.
Zurück zum Zitat Camandola S, Poli G, Mattson MP (2000) The lipid peroxidation product 4-hydroxy-2,3-nonenal inhibits constitutive and inducible activity of nuclear factor kappa B in neurons. Brain Res Mol Brain Res 85:53–60CrossRef Camandola S, Poli G, Mattson MP (2000) The lipid peroxidation product 4-hydroxy-2,3-nonenal inhibits constitutive and inducible activity of nuclear factor kappa B in neurons. Brain Res Mol Brain Res 85:53–60CrossRef
16.
Zurück zum Zitat Lee SI, Kim BS, Kim KS, Lee S, Shin KS, Lim JS (2008) Immunosuppressive activity of punicalagin via inhibition of NFAT activation. Biochem Biophys Res Commun 371:799–803CrossRef Lee SI, Kim BS, Kim KS, Lee S, Shin KS, Lim JS (2008) Immunosuppressive activity of punicalagin via inhibition of NFAT activation. Biochem Biophys Res Commun 371:799–803CrossRef
17.
Zurück zum Zitat Romier B, Van De Walle J, During A, Larondelle Y, Schneider YJ (2008) Modulation of signalling nuclear factor-kappaB activation pathway by polyphenols in human intestinal Caco-2 cells. Br J Nutr 100:542–551CrossRef Romier B, Van De Walle J, During A, Larondelle Y, Schneider YJ (2008) Modulation of signalling nuclear factor-kappaB activation pathway by polyphenols in human intestinal Caco-2 cells. Br J Nutr 100:542–551CrossRef
18.
Zurück zum Zitat Oucharif A, Khalki H, Chaib S, Mountassir M, Aboufatima R, Farouk L, Benharraf A, Chait A (2012) Comparative study of the anti-inflammatory and antinociceptive effects of two varieties of Punica granatum. Pharm Biol 50:429–438CrossRef Oucharif A, Khalki H, Chaib S, Mountassir M, Aboufatima R, Farouk L, Benharraf A, Chait A (2012) Comparative study of the anti-inflammatory and antinociceptive effects of two varieties of Punica granatum. Pharm Biol 50:429–438CrossRef
19.
Zurück zum Zitat Lee CJ, Chen LG, Liang WL, Wang CC (2010) Anti-inflammatory effects of Punica granatum Linne in vitro and in vivo. Food Chem 118:315–322CrossRef Lee CJ, Chen LG, Liang WL, Wang CC (2010) Anti-inflammatory effects of Punica granatum Linne in vitro and in vivo. Food Chem 118:315–322CrossRef
20.
Zurück zum Zitat Olajide OA, Kumar A, Velagapudi R, Okorji U, Fiebich BL (2014) Punicalagin inhibits neuroinflammation in LPS-activated rat primary microglia. Mol Nutr Food Res 58:1843–1851CrossRef Olajide OA, Kumar A, Velagapudi R, Okorji U, Fiebich BL (2014) Punicalagin inhibits neuroinflammation in LPS-activated rat primary microglia. Mol Nutr Food Res 58:1843–1851CrossRef
21.
Zurück zum Zitat Seeram NP, Lee R, Hardy ML, Heber D (2005) Large scale purification of ellagitannins from pomegranate husk, a by-product of the commercial juice industry. Sep Purif Technol 41:49–55CrossRef Seeram NP, Lee R, Hardy ML, Heber D (2005) Large scale purification of ellagitannins from pomegranate husk, a by-product of the commercial juice industry. Sep Purif Technol 41:49–55CrossRef
22.
Zurück zum Zitat Olajide OA, Velagapudi R, Okorji U, Sarker S, Fiebich BL (2014) Picralima nitida seeds suppress PGE2 production by interfering with multiple signalling pathways in IL-1β-stimulated SK-N-SH neuronal cells. J Ethnopharmacol 152:377–383CrossRef Olajide OA, Velagapudi R, Okorji U, Sarker S, Fiebich BL (2014) Picralima nitida seeds suppress PGE2 production by interfering with multiple signalling pathways in IL-1β-stimulated SK-N-SH neuronal cells. J Ethnopharmacol 152:377–383CrossRef
23.
Zurück zum Zitat Decker T, Lohmann-Matthes ML (1988) A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J Immunol Methods 115:61–69CrossRef Decker T, Lohmann-Matthes ML (1988) A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J Immunol Methods 115:61–69CrossRef
24.
Zurück zum Zitat Sutinen EM, Pirttilä T, Anderson G, Salminen A, Ojala JO (2012) Pro-inflammatory interleukin-18 increases Alzheimer’s disease-associated amyloid-β production in human neuron-like cells. J Neuroinflamm 9:199CrossRef Sutinen EM, Pirttilä T, Anderson G, Salminen A, Ojala JO (2012) Pro-inflammatory interleukin-18 increases Alzheimer’s disease-associated amyloid-β production in human neuron-like cells. J Neuroinflamm 9:199CrossRef
25.
Zurück zum Zitat Pasinetti GM, Aisen PS (1998) Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer’s disease brain. Neuroscience 87:319–324CrossRef Pasinetti GM, Aisen PS (1998) Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer’s disease brain. Neuroscience 87:319–324CrossRef
26.
Zurück zum Zitat Lim GP, Yang F, Chu T, Chen P, Beech W, Teter B, Tran T, Ubeda O, Ashe KH, Frautschy SA, Cole GM (2000) Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer’s disease. J Neurosci 20:5709–5714 Lim GP, Yang F, Chu T, Chen P, Beech W, Teter B, Tran T, Ubeda O, Ashe KH, Frautschy SA, Cole GM (2000) Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer’s disease. J Neurosci 20:5709–5714
27.
Zurück zum Zitat Romier-Crouzet B, Van De Walle J, During A, Joly A, Rousseau C, Henry O, Larondelle Y, Schneider YJ (2009) Inhibition of inflammatory mediators by polyphenolic plant extracts in human intestinal Caco-2 cells. Food Chem Toxicol 47:1221–1230CrossRef Romier-Crouzet B, Van De Walle J, During A, Joly A, Rousseau C, Henry O, Larondelle Y, Schneider YJ (2009) Inhibition of inflammatory mediators by polyphenolic plant extracts in human intestinal Caco-2 cells. Food Chem Toxicol 47:1221–1230CrossRef
28.
Zurück zum Zitat Ahmed S, Wang N, Hafeez BB, Cheruvu VK, Haqqi TM (2005) Punica granatum L. extract inhibits IL–1beta-induced expression of matrix metalloproteinases by inhibiting the activation of MAP kinases and NF-kappa B in human chondrocytes in vitro. J Nutr 135:2096–2102 Ahmed S, Wang N, Hafeez BB, Cheruvu VK, Haqqi TM (2005) Punica granatum L. extract inhibits IL–1beta-induced expression of matrix metalloproteinases by inhibiting the activation of MAP kinases and NF-kappa B in human chondrocytes in vitro. J Nutr 135:2096–2102
29.
Zurück zum Zitat Sinha S, Anderson JP, Barbour R, Basi GS, Caccavello R, Davis D, Doan M, Dovey HF, Frigon N, Hong J, Jacobson-Croak K, Jewett N, Keim P, Knops J, Lieberburg I, Power M, Tan H, Tatsuno G, Tung J, Schenk D, Seubert P, Suomensaari SM, Wang S, Walker D, Zhao J, McConlogue L, John V (1999) Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature 402:537–540CrossRef Sinha S, Anderson JP, Barbour R, Basi GS, Caccavello R, Davis D, Doan M, Dovey HF, Frigon N, Hong J, Jacobson-Croak K, Jewett N, Keim P, Knops J, Lieberburg I, Power M, Tan H, Tatsuno G, Tung J, Schenk D, Seubert P, Suomensaari SM, Wang S, Walker D, Zhao J, McConlogue L, John V (1999) Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature 402:537–540CrossRef
30.
Zurück zum Zitat Luo Y, Bolon B, Kahn S, Bennett BD, Babu-Khan S, Denis P, Fan W, Kha H, Zhang J, Gong Y, Martin L, Louis JC, Yan Q, Richards WG, Citron M, Vassar R (2001) Mice deficient in BACE1, the Alzheimer’s beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat Neurosci 4:231–232CrossRef Luo Y, Bolon B, Kahn S, Bennett BD, Babu-Khan S, Denis P, Fan W, Kha H, Zhang J, Gong Y, Martin L, Louis JC, Yan Q, Richards WG, Citron M, Vassar R (2001) Mice deficient in BACE1, the Alzheimer’s beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat Neurosci 4:231–232CrossRef
31.
Zurück zum Zitat Lei F, Xing DM, Xiang L, Zhao YN, Wang W, Zhang LJ, Du LJ (2003) Pharmacokinetic study of ellagic acid in rat after oral administration of pomegranate leaf extract. J Chromatogr B Analyt Technol Biomed Life Sci 796:189–194CrossRef Lei F, Xing DM, Xiang L, Zhao YN, Wang W, Zhang LJ, Du LJ (2003) Pharmacokinetic study of ellagic acid in rat after oral administration of pomegranate leaf extract. J Chromatogr B Analyt Technol Biomed Life Sci 796:189–194CrossRef
32.
Zurück zum Zitat Shukla M, Gupta K, Rasheed Z, Khan KA, Haqqi TM (2008) Bioavailable constituents/metabolites of pomegranate (Punica granatum L) preferentially inhibit COX2 activity ex vivo and IL–1beta-induced PGE2 production in human chondrocytes in vitro. J Inflamm (Lond) 5:9CrossRef Shukla M, Gupta K, Rasheed Z, Khan KA, Haqqi TM (2008) Bioavailable constituents/metabolites of pomegranate (Punica granatum L) preferentially inhibit COX2 activity ex vivo and IL–1beta-induced PGE2 production in human chondrocytes in vitro. J Inflamm (Lond) 5:9CrossRef
33.
Zurück zum Zitat Seeram NP, Lee R, Heber D (2004) Bioavailability of ellagic acid in human plasma after consumption of ellagitannins from pomegranate (Punica granatum L.) juice. Clin Chim Acta 348:63–68CrossRef Seeram NP, Lee R, Heber D (2004) Bioavailability of ellagic acid in human plasma after consumption of ellagitannins from pomegranate (Punica granatum L.) juice. Clin Chim Acta 348:63–68CrossRef
34.
Zurück zum Zitat Bialonska D, Kasimsetty SG, Khan SI, Ferreira D (2009) Urolithins, intestinal microbial metabolites of Pomegranate ellagitannins, exhibit potent antioxidant activity in a cell-based assay. J Agric Food Chem 57:10181–10186CrossRef Bialonska D, Kasimsetty SG, Khan SI, Ferreira D (2009) Urolithins, intestinal microbial metabolites of Pomegranate ellagitannins, exhibit potent antioxidant activity in a cell-based assay. J Agric Food Chem 57:10181–10186CrossRef
35.
Zurück zum Zitat Farbood Y, Sarkaki A, Dianat M, Khodadadi A, Haddad MK, Mashhadizadeh S (2015) Ellagic acid prevents cognitive and hippocampal long-term potentiation deficits and brain inflammation in rat with traumatic brain injury. Life Sci 124:120–127CrossRef Farbood Y, Sarkaki A, Dianat M, Khodadadi A, Haddad MK, Mashhadizadeh S (2015) Ellagic acid prevents cognitive and hippocampal long-term potentiation deficits and brain inflammation in rat with traumatic brain injury. Life Sci 124:120–127CrossRef
Metadaten
Titel
Pomegranate inhibits neuroinflammation and amyloidogenesis in IL-1β-stimulated SK-N-SH cells
verfasst von
Ravikanth Velagapudi
Gina Baco
Sunjeet Khela
Uchechukwu Okorji
Olumayokun Olajide
Publikationsdatum
10.07.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Nutrition / Ausgabe 4/2016
Print ISSN: 1436-6207
Elektronische ISSN: 1436-6215
DOI
https://doi.org/10.1007/s00394-015-0984-0

Weitere Artikel der Ausgabe 4/2016

European Journal of Nutrition 4/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

VHF-Ablation nützt wohl nur bei reduzierter Auswurfleistung

02.05.2024 Ablationstherapie Nachrichten

Ob die Katheterablation von Vorhofflimmern bei Patienten mit Herzinsuffizienz die Komplikationsraten senkt, scheint davon abzuhängen, ob die Auswurfleistung erhalten ist oder nicht. Das legen die Ergebnisse einer Metaanalyse nahe.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.